


Abou-Donia, M., personal communication, 1998.


Abou-Donia, M., K. Wilmarth, et al., “Increased Neurotoxicity Following Simultaneous Exposure to Pyridostigmine Bromide (PB), Deet, and Chlorpyrifos,”
Joint Meeting of the American Society for Biochemistry and Molecular Biology, American Society for Investigative Pathology, and the American Association of Immunologists, FASEB Journal, 1996c.


Albuquerque, E., A. Boyne, et al., “Molecular and Behavioral Studies of Anti-
cholinesterase Agents on Various Receptor Targets in the Peripheral and 
Central Nervous System: Acute and Chronic Studies Using Biophysical, Bio-
chemical, Histological and Therapeutic Approaches,” Fort Detrick, Md.: U.S. 
Army Medical Research and Development Command. Contract DAMD17-81-
C-1279, 1983.

Albuquerque, E., A. Boyne, et al., “The Molecular Targets of Selected 
Organophosphorus Compounds at Nicotinic, Muscarinic, GABA, and Gluta-
mate Synapses: Acute and Chronic Studies Using Biophysical, Biochemical, 
Histological and Therapeutic Approaches,” Fort Detrick, Md.: U.S. Army 
Medical Research and Development Command, annual report, Contract 
DAMD17-81-C-1279, 1995.

Albuquerque, E., A. Costa, et al., “Functional Properties of the Nicotinic and 

Albuquerque, E., S. Deshpande, et al., “Multiple Actions of Anticholinesterase 
Agents on Chemosensitive Synapses: Molecular Basis for Prophylaxis and 
Treatment of Organophosphate Poisoning,” Fundam Appl Toxicol, 5, 1985, 
S182–S203.

Albuquerque, E., E. Pereira, et al., “Nicotinic Receptor Function in the Mam-

Albuquerque, E., E. Pereira, et al., “Nicotinic Acetylcholine Receptors on Hippo-
campal Neurons: Distribution on the Neuronal Surface and Modulation of 
Receptor Activity,” J of Receptor and Signal Transduction Research, 17(1-3), 
1997, pp. 243–266.


Alkondon, M., and E. Albuquerque, “Diversity of Nicotinic Acetylcholine Recep-
tors in Rat Hippocampal Neurons. I. Pharmacological and Functional Evi-
dence for Distinct Structural Subtypes,” J Pharmacol Exp Therapeutics, 
265(3), 1993, pp. 1455–1473.

Alkondon, M., E. Rocha, et al., “Diversity of Nicotinic Acetylcholine Receptors in 
Rat Brain V. Alpha Bungarotoxin-Sensitive Nicotinic Receptors in Olfactory 

Allan, W., “Bromism and Iodism in Gulf War and Other Illness,” Internet report, 


Augerson, W., A Review of the Scientific Literature As It Pertains to Gulf War Illnesses, Vol. 5: Chemical and Biological Warfare Agents, Santa Monica, Calif.: RAND, MR-1018/5, forthcoming.


Baumsweiger, W., personal communication, 1998.


Capacio, B., I. Koplovitz, et al., “Drug Interaction Studies of Pyridostigmine with the 5HT3 Receptor Antagonist Ondansetron and Granisetron in Guinea


De Fraites, R., “Pyridostigmine Bromide (PB) Use in Operations Desert Shield and Desert Storm (ODS),” information paper, DASG-HS-PM, 1996.


Department of Defense, comments on Public Citizen Litigation Group’s Petition to Repeal Interim Rule on the Treatment Use Without Informed Consent of Investigational New Drugs in Military Combat Exigency, 1996.


Dvorska, I., et al., “On the Blood-Brain Barrier to Peptides: Effects of Immo-
obilization Stress on Regional Blood Supply and Accumulation of Labeled

Dwyer, J., USC Department of Research, personal communication, 1998.

Eakman, G., J. Dallas, et al., “The Effects of Testosterone and Dihydro-
testosterone on Hypothalamic Regulation of Growth Hormone Secretion,” J

Eastwood, J., G. Levine, et al., “Aluminium Deposition in Bone After Contam-

Eaton, L., and E. Lambert, “Electromyography and Electrical Stimulation of

Eberly, R., and B. Engdahl, “Prevalence of Somatic and Psychiatric Disorders
Among Foreign Prisoners of War,” Hospital and Community Psychiatry,

Ecobichon, D., J. Davies, et al., “Neurotoxic Effects of Pesticides, in S. Baker and
C. Wilkinson, eds., The Effect of Pesticides on Human Health, Princeton, N. J.: Prin-

Edwards, D., and C. Johnson, “Insect-Repellent-Induced Toxic Encephalopathy

Ehlert, F., N. Kokka, et al., “Altered (3H)-Quinuclidinyl Benzilate Binding in the
Striatum of Rats Following Chronic Cholinesterase Inhibition with Di-

Ehlert, F., N. Kokka, et al., “Muscarinic Subsensitivity in the Longitudinal Mus-
cle of the Rat Ileum Following Anticholinesterase Treatment with Di-

Ehrich, M., L. Shell, et al., “Short-Term Clinical and Neuropathologic Effects of
Cholinesterase Inhibitors in Rats,” J Am Coll Toxicol, 12, 1993, pp. 55–67.

Eichelman, B., “Role of Biogenic Amines in Aggressive Behavior,” in M. Sandler,
93.

Eiermann, B., N. Sommer, et al., “Renal Clearance of Pyridostigmine in Myas-
thenia Patients and Volunteers Under the Influence of Ranitidine and Piren-
zepine,” Xenobiotica, 23, 1993, pp. 1263–1175.

El-Fakahany, E., and E. Richelson, “Involvement of Calcium Channels in Short-
Term Desensitization of Muscarinic Receptor-Mediated Cyclic G–P For-
6897–6901.


Eriksson, P. U. Johansson, et al., “Neonatal Exposure to DDT Induces Increased Susceptibility to Pyrethroid (Bioallethrin) Exposure at Adult Age—Changes in


FDA, personal communication with Stuart Nightingale, Brian Malkin, and others regarding PB, 1997.


Fiedler, N., H. Kipen, et al., “Chemical Sensitivities and the Gulf War: Department of Veterans Affairs Research Center in Basic and Clinical Science Stud-


Hane, D., “Acute Toxicity Studies in Mice, Rats, Rabbits, and Dogs with Pyridostigmine Bromide (Ro 1-5130) and Ro1-5237/000,” Nutley, N.J., Roche Laboratories (internal report), 1977.


Health Services, Office of the Surgeon General, “Pyridostigmine Bromide (PB) Use in Operations Desert Shield and Desert Storm (ODS),” October 2, 1996.


Leber, P., letter from Director, Division of Neuropharmacological Drug Products, Office of Drug Evaluation I, Center for Drug Evaluation and Research, to


Meggs, W., and C. Cleveland, “Rhinolaryngoscopic Examination of Patients with the Multiple Chemical Sensitivity Syndrome,” Arch Environ Health, 48(1), 1993, pp. 14–18.


Miller, C., “Chemical Sensitivity: Symptom, Syndrome, or Mechanism for Disease?” Toxicology, 111, 1996a, pp. 69–86.

Miller, C., invited testimony, Committee on Government Reform and Oversight, Subcommittee on Human Resources and Intergovernmental Relations, U.S. House of Representatives, 1996b.

Miller, C., invited presentation, Presidential Advisory Committee on Gulf War Veterans’ Illnesses, 1996c.


Prendergast, M., statement by Deputy Commissioner and Senior Advisor to the Commissioner, Food and Drug Administration, Department of Health and Human Services, before the Presidential Advisory Committee on Gulf War Veterans’ Illnesses, 1997.


Pyridostigmine Bromide New Drug Application (pending), filed May 1996.


Rothrock, J., “Making Sense of the New Migraine Drugs,” UCSD Department of Medicine, Grand Rounds, La Jolla, Calif., January 12, 1999.


Sidell, F., clinical notes on chemical casualty care: pyridostigmine, Aberdeen Proving Ground, M.d.: U.S. Army Medical Research Institute of Chemical Defense, Department of the Army, 1990.


Soreq, H., “Acetylcholinesterase: The Problem or the Solution?” (abstract), CDC Conference on The Health Impact of Chemical Exposures During the Gulf War, Atlanta, Ga., February 28–March 2, 1999.


References 377


Young, G. D., “Pyridostigmine Bromide Interactive Studies: A Synopsis of Past,
Current, and Future Studies,” Directorate of Toxicology, USACHPPM, undated.

Young, J., “Desensitization and Agonist Binding to Cholinergic Receptors in

Young, R., R. Rachal, and J. W. Huguley III, “Environmental Health Concerns of

Zadikoff, C., “Toxic Encephalopathy Associated with Use of Insect Repellent,” J


Zeller, M., prepared statement of SSgt. Mark J. Zeller before the Subcommittee
on Human Resources, House Committee on Government Reform and Over-

Zhou, Y. F., E. Guetta, et al., “Human Cytomegalovirus Increases Modified Low
Density Lipoprotein Uptake and Scavenger Receptor mRNA Expression in

Ziem, G., “Multiple Chemical Sensitivity: Treatment and Followup with Avoid-
ance and Control of Chemical Exposures,” Toxicol Ind Health, 8, 1992, pp.
73–86.

Ziem, G., and J. McTamney, “Profile of Patients with Chemical Injury and Sen-
sitivity,” Environmental Health Perspectives, 105, 1997, Supplement 2, pp.
417–436.

Zoler, M., “Vagal-Nerve Stimulation Needs Tweaking,” Internal Medicine News,

Zuckerman, D., P. Olson, et al., “Is Military Research Hazardous to Veterans’